Objective: Both estrogen receptors, ER alpha ($ER{alpha}$) and ER beta ($ER{eta}$), are expressed in 50-70% of breast cancer cases. The role of $ER{alpha}$ as a prognostic marker in breast cancer has been well established as its expression is negative correlated with tumor size and lymph node metastasis. $ER{eta}$ is also a favorable prognostic predictor although this is less well documented than for $ER{alpha}$. Materials and Methods: To explore whether ERs independently or together might influence clinical outcome in breast cancer, the correlation between the ERs with the clinicopathological features was analyzed in 84 patients. Results: $ER{alpha}$ expression negatively correlated with tumor stage (r=-0.246, p=0.028) and tended to be negatively correlated with lymph node status (r=-0.156, p=0.168) and tumor size (r=-0.246, p=0.099). Also, $ER{eta}$ was negatively correlated with nodal status (r=-0.243, p=0.028), as was coexpression of $ER{alpha}$ and $ER{eta}$ (p=0.043, OR=0.194, 95% CI= 0.040-0.953). Conclusion: Coexpression of ERs might serve as an indicator of good prognosis in breast cancer patients.